Supplementary Table 1.
Outcomes of included patients with dysnatremia.
| Group | AKI, n (%) | Death, n (%) | Length of hospital stay, days | Hospital cost, RMB |
|---|---|---|---|---|
| Model 1 | ||||
| Normonatremia | 6,149 (8.3) | 317 (0.4) | 5.0 (2.5–8.0) | 13,869.1 (7,669.2–32,798.7) |
| Hyponatremia | 4,446 (29.2) | 439 (2.9) | 10.0 (5.5–15.0)# | 29,533.5 (13,362.4–60,616.8)# |
| Hypernatremia | 764 (45.3) | 204 (12.1) | 10.5 (6.0–17.0)# | 37,104.3 (14,016.3–80,466.7)# |
| Mixed dysnatremia | 233 (81.8) | 69 (24.2) | 21.0 (13.5–32.5)# | 106,510.3 (46,623.5–180,214.8)# |
| P value (χ2 or ANOVA) | 0.000 | 0.000 | 0.000 | 0.000 |
| Model 2 | ||||
| CA-hyponatremia | 1,677 (23.8) | 291 (4.1) | 7.0 (4.0–12.5) | 16,176.1 (9,060.1–33,854.8) |
| HA-hyponatremia | 2,769 (33.9) | 148 (1.8) | 11.5 (8.0–16.5) | 46,061.3 (23,207.6–83,343.8) |
| P value | 0.000 | 0.000 | 0.000 | 0.000 |
| CA-hypernatremia | 247 (29.1) | 83 (9.8) | 7.0 (3.5–12.5) | 20,248.1 (9,198.2–46,825.4) |
| HA-hypernatremia | 517 (61.8) | 121 (14.5) | 14.0 (9.5–21.5) | 60,351.1 (29,892.6–121,096.3) |
| P value | 0.000 | 0.003 | 0.000 | 0.000 |
| Model 3 | ||||
| Improved hyponatremia | 1,888 (36.2) | 176 (3.4) | 12.5 (8.5–18.5) | 41,283.8 (20,389.7–71,168.3) |
| Persistent hyponatremia | 2,558 (25.5) | 263 (2.6) | 8.0 (4.5–13.5) | 22,206.9 (11,558.2–54,202.7) |
| P value | 0.000 | 0.008 | 0.000 | 0.000 |
| Improved hypernatremia | 488 (56.8) | 61 (7.1) | 14.0 (9.5–21.0) | 57,157.7 (30,575.9–116,872.8) |
| Persistent hypernatremia | 276 (33.3) | 143 (17.3) | 7.0 (3.5–12.0) | 17,773.6 (8,782.9–49,237.5) |
| P value | 0.000 | 0.000 | 0.000 | 0.000 |
| “Hypo to hyper” mixed dysnatremia | 82 (35.2) | 55 (79.7) | 21.8 (13.4–38.5) | 89,939.4 (29,995.7–180,373.3) |
| “Hyper to hypo” mixed dysnatremia | 151 (64.8) | 14 (20.3) | 20.5 (14.0–30.5) | 113,523 (52,375.1–181,003.8) |
| P value | 0.657 | 0.000 | 0.603 | 0.050 |
#
P<0.001 vs. normonatremia group.
AKI – acute kidney injury; RMB – Ren Min Bi; CA – community-acquired; HA – hospital-acquired.